Entrada Therapeutics, Inc.
TRDA
$8.16
-$0.17-2.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 65.63M | 54.95M | 104.44M | 23.49M | -6.69M |
| Total Depreciation and Amortization | 3.77M | 3.52M | 3.41M | 3.23M | 2.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.90M | 7.55M | 7.44M | 6.51M | 7.33M |
| Change in Net Operating Assets | -118.85M | -79.98M | -129.49M | -122.34M | 136.32M |
| Cash from Operations | -41.56M | -13.97M | -14.19M | -89.12M | 139.80M |
| Capital Expenditure | -3.16M | -3.50M | -4.31M | -4.78M | -5.61M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.64M | -58.62M | 21.38M | -67.02M | -132.78M |
| Cash from Investing | -27.80M | -62.12M | 17.07M | -71.80M | -138.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 102.98M | 102.26M | 102.63M | 1.71M | 21.04M |
| Repurchase of Common Stock | -11.00K | -11.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 102.96M | 102.25M | 102.63M | 1.71M | 21.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.61M | 26.17M | 105.51M | -159.21M | 22.45M |